Free tool
FAERS Monitor: Tadliq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214522 or its brand name (Tadliq, Tadalafil). Reports on generic versions are filed under their own applications.
Reports
32,516
Serious
21,489
66% of reports
Hospitalization
12,806
Death reported
3,167
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea4,261
- headache3,819
- diarrhoea3,154
- nausea2,569
- fatigue2,536
- cough2,047
- dizziness1,957
- death1,528
- off label use1,355
- vomiting1,330
- drug ineffective1,276
- pneumonia1,255
- pain1,233
- hypotension1,186
- malaise1,148
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 24 |
| 2005 | 13 |
| 2006 | 15 |
| 2007 | 37 |
| 2008 | 26 |
| 2009 | 43 |
| 2010 | 81 |
| 2011 | 185 |
| 2012 | 120 |
| 2013 | 165 |
| 2014 | 213 |
| 2015 | 257 |
| 2016 | 431 |
| 2017 | 408 |
| 2018 | 972 |
| 2019 | 2,934 |
| 2020 | 2,680 |
| 2021 | 2,876 |
| 2022 | 3,544 |
| 2023 | 4,261 |
| 2024 | 4,578 |
| 2025 | 5,104 |
| 2026 | 3,549 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyspnoeaSignal | 4,261 | 4.9 | 4.8 | 13,478 |
| coughSignal | 2,047 | 4.7 | 4.6 | 6,091 |
| headacheSignal | 3,819 | 4.0 | 3.8 | 8,646 |
| hypotensionSignal | 1,186 | 3.8 | 3.6 | 2,499 |
| diarrhoeaSignal | 3,154 | 3.2 | 3.1 | 4,811 |
| dizzinessSignal | 1,957 | 2.5 | 2.4 | 1,870 |
| pneumoniaSignal | 1,255 | 2.5 | 2.4 | 1,155 |
| fatigueSignal | 2,536 | 2.1 | 2.0 | 1,533 |
| nauseaSignal | 2,569 | 2.1 | 2.0 | 1,539 |
| vomiting | 1,330 | 1.8 | 1.7 | 512 |
| malaise | 1,148 | 1.7 | 1.6 | 332 |
| pain | 1,233 | 1.3 | 1.2 | 87 |
| death | 1,528 | 1.1 | 1.1 | 30 |
| off label use | 1,355 | 1.0 | 1.0 | 0 |
| drug ineffective | 1,276 | 0.6 | 0.6 | 304 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.